Company: CERO
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-044335
Chunk: 51

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 1
Chunk 51
---
2024 for the Company is presented below:

    Level 1  
    Level 2  
    Level 3  
    Total 
  
    Preferred stock warrant liability (Predecessor): 

    Balance at December 31, 2023 
    $     -  
    $     -  
    $320,117  
     320,117 
  
    Reclassification of warrant liability to equity 
     -  
     -  
     (320,117) 
     (320,117)
  
    Balance at February 13, 2024 
    $-  
    $-  
    $-  
    $- 

    Earnout liability (Successor): 

    Balance at February 14, 2024 
     -  
     -  
     4,900,000  
     4,900,000 
  
    Gain on revaluation of earnout liability 
     -  
     -  
     (1,800,000) 
     (1,800,000)
  
    Balance at March 31, 2024 
    $-  
    $-  
    $3,100,000  
    $3,100,000 
  
    Earnout liability (Successor): 

    Balance at December 31, 2024 
     -  
     -  
     20,000  
     20,000 
  
    Gain on revaluation of earnout liability 
     -  
     -  
     -  
     - 
  
    Balance at March 31, 2025 
    $-  
    $-  
    $20,000  
    $20,000 

NOTE 11 – STOCK-BASED COMPENSATION

On March 25, 2024, stockholders approved the 2024
Equity Incentive Plan (2024 Plan) and 2024 Employee Stock Purchase Plan (2024 ESPP), with initial reserves of 51,726 and 5,099 shares
of common stock, respectively. The 2024 Plan and 2024 ESPP became effective on February 14, 2024. No awards have been granted under the
2024 ESPP as of March 31, 2025.

Stockholders approved increases in shares